Ardent Health
Ardent Health's revenue rose 6.0% to $6.3 billion in fiscal 2025. Its net margin was 2.1%, down from 3.5% a year earlier. The diluted share count rose 6.6%.
Net margin is net income as a share of revenue. Free cash flow is cash from operations minus capital spending. Return on equity is net income as a share of shareholders' equity. Market cap is the last closing share price times the latest diluted share count, so it is approximate. P/E is the last close divided by diluted earnings per share over the last four quarters, or the latest fiscal year where the quarters aren't available; there is none when the company made a loss.
Charts show fiscal years, from the 10-K filings.
What Ardent Health does
Ardent Health is a holding company whose affiliates run acute care hospitals and other health care facilities and employ physicians. It operates in eight mid-sized urban markets across six states: Texas, Oklahoma, New Mexico, New Jersey, Idaho and Kansas.
It provides general and specialty services, such as internal medicine, surgery, cardiology, oncology, orthopedics, women's services, neurology, urology and emergency care, both in hospitals and in outpatient settings. It also runs clinics and telehealth services. It reports one segment, health care services, and earns its revenue from patient care, paid largely by government programs like Medicare and Medicaid and by commercial insurers.
Ardent often works through joint ventures with academic medical centers, not-for-profit hospital systems and community physicians. It describes this joint venture model as a key part of how it operates. It became a public company through an initial public offering in July 2024.
Its biggest risks, as it describes them
- Changes in Medicare, Medicaid and other government health care programs could cut its revenue.
- Competition in its markets could reduce patient volumes.
- Trouble recruiting and keeping physicians, nurses and other staff, and the cost of labor.
- Its growth depends on completing acquisitions and joint ventures on acceptable terms.
Income statement
From fiscal 2022 to 2025, earnings per share fell 13.8% a year and net income 10.4% a year, as new shares raised the share count by 12% and diluted each share's earnings.
Returns on capital
Balance sheet
Five years at a glance
| Fiscal year end | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|
| Cash and short-term investments | 456 | 438 | 557 | 710 |
| Debt incl. finance leases | — | 1,209 | 1,135 | 1,140 |
| Net debt (negative means net cash) | — | 771 | 578 | 431 |
| Net debt to EBITDA | — | — | — | — |
| Debt to equity | — | 1.8x | 1.0x | 0.9x |
| Interest coverage | — | — | — | — |
| Current ratio | — | 1.6x | 1.9x | 2.0x |
| Quick ratio | — | 1.5x | 1.8x | 1.9x |
Cash flow
Free cash flow is cash from operations minus capital expenditure. The SEC's structured data for Ardent Health's filings doesn't give both for any year, so free cash flow is left out.
Projections
Project Ardent Health's revenue, net income and earnings per share five years ahead in a bull, a base and a bear case with your own figures, and see the share prices your P/E estimates give them, or value it with a discounted cash flow model. Every projected figure is yours: it is not a forecast of ours.
What Ardent Health says to expect
- Full year 2026: adjusted EBITDA and revenue
The Company is increasing its full-year 2026 adjusted EBITDA financial guidance to $500 – 535 million from $485 – 535 million . The Company is maintaining its full-year 2026 revenue outlook of $6,400 – 6,700 million .
Insider trades
Over the 12 months between November 20, 2025 and November 19, 2026, 2 insiders bought $186,400 of Ardent Health shares on the open market, and none sold any.
| Date | Insider | Trade | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| Jun 5, 2026 | Robert DeMichieiDirector | Bought | 11,260 | $8.73 | $98,300 | Form 4 |
| Jun 5, 2026 | Alfred LumsdaineChief Financial Officer | Bought | 10,000 | $8.81 | $88,100 | Form 4 |
Indicators
Four widely used measures, worked out from the company's filings. The cutoffs are the ones their authors or users go by, not a verdict of ours.
| Indicator | FY23 | FY24 | FY25 |
|---|---|---|---|
| Piotroski F-score | — | — | 6 of 8 |
| Rule of 40 | — | — | — |
| Altman Z'' | — | — | — |
| Accruals ratio | — | −2.2% | −6.5% |
The nine F-score tests
| Test | FY23 | FY24 | FY25 |
|---|---|---|---|
| Net income is positive | — | Pass | Pass |
| Cash from operations is positive | Pass | Pass | Pass |
| Return on assets rose | — | — | Fail |
| Cash from operations exceeds net income | Pass | Pass | Pass |
| Debt fell relative to assets | — | — | Pass |
| Current ratio rose | — | Pass | Pass |
| Share count didn't rise | Pass | Fail | Fail |
| Gross margin rose | — | — | — |
| Revenue rose relative to assets | — | — | Pass |
| F-score | — | — | 6 of 8 |
Compare
Put Ardent Health side by side with any other company we cover: revenue, growth, margins, cash flow and returns, with ten years of charts.
Similar companies
| Company | Year | Revenue growth | Operating margin | Free cash flow margin | Return on capital | Net debt to EBITDA | F-score | Compare |
|---|---|---|---|---|---|---|---|---|
| Ardent Health | FY25 | 6.0% | — | — | — | — | 6 | |
| Encompass Health | FY25 | 10.5% | — | 7.4% | 15.8% | 1.7x | 8 | Compare |
| Option Care Health | FY25 | 13.0% | 6.0% | 3.8% | 11.4% | 2.3x | 5 | Compare |
| PACS Group | FY25 | 29.3% | 5.8% | 5.7% | 17.5% | — | 6 | Compare |
| Ensign Group | FY25 | 18.7% | 8.4% | — | 19.7% | −0.8x | 6 | Compare |
4 years of figures
| Fiscal year | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|
| Income statement | ||||
| Revenue | 5,130 | 5,410 | 5,966 | 6,324 |
| Revenue growth | — | 5.5% | 10.3% | 6.0% |
| Gross profit | — | — | — | — |
| Research and development | — | — | — | — |
| Operating income | — | — | — | — |
| Net income | 189 | 54 | 210 | 136 |
| Diluted EPS (US$) | 1.50 | 0.43 | 1.58 | 0.96 |
| Diluted shares (millions) | 126 | 126 | 133 | 142 |
| Cash flow | ||||
| Cash from operations | −38 | 222 | 315 | 470 |
| Capital expenditure | — | — | — | — |
| Free cash flow | — | — | — | — |
| Dividends paid | 175 | 0 | 0 | 0 |
| Share buybacks | 0 | 0 | 0 | 0 |
| Acquisitions | 0 | 0 | 36 | 2 |
| Stock-based compensation | — | — | — | — |
| Balance sheet at fiscal year end | ||||
| Cash and short-term investments | 456 | 438 | 557 | 710 |
| Debt incl. finance leases | — | 1,209 | 1,135 | 1,140 |
| Total assets | — | 4,732 | 4,956 | 5,290 |
| Total liabilities | — | 3,649 | 3,434 | 3,605 |
| Shareholders' equity | 1,040 | 671 | 1,131 | 1,288 |
| Margins and ratios | ||||
| Gross margin | — | — | — | — |
| Operating margin | — | — | — | — |
| Net margin | 3.7% | 1.0% | 3.5% | 2.1% |
| Free cash flow margin | — | — | — | — |
| Rule of 40 (growth + FCF margin) | — | — | — | — |
| Return on capital | — | — | — | — |
| Return on equity | — | — | 23.3% | 11.2% |
| Return on assets | — | — | 4.3% | 2.6% |
| Net debt to EBITDA | — | — | — | — |